JP2005519891A - 危篤状態の患者における罹病率および死亡率を低下させる方法 - Google Patents

危篤状態の患者における罹病率および死亡率を低下させる方法 Download PDF

Info

Publication number
JP2005519891A
JP2005519891A JP2003559435A JP2003559435A JP2005519891A JP 2005519891 A JP2005519891 A JP 2005519891A JP 2003559435 A JP2003559435 A JP 2003559435A JP 2003559435 A JP2003559435 A JP 2003559435A JP 2005519891 A JP2005519891 A JP 2005519891A
Authority
JP
Japan
Prior art keywords
fgf
critically ill
ill patients
patient
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003559435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519891A5 (https=
Inventor
ジョゼフ・ジョージ・ヒューアー
アレクセイ・カリトネンコフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2005519891A publication Critical patent/JP2005519891A/ja
Publication of JP2005519891A5 publication Critical patent/JP2005519891A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2003559435A 2002-01-15 2003-01-08 危篤状態の患者における罹病率および死亡率を低下させる方法 Pending JP2005519891A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34889002P 2002-01-15 2002-01-15
PCT/US2003/000010 WO2003059270A2 (en) 2002-01-15 2003-01-08 Method for reducing morbidity and mortality in critically ill patients

Publications (2)

Publication Number Publication Date
JP2005519891A true JP2005519891A (ja) 2005-07-07
JP2005519891A5 JP2005519891A5 (https=) 2006-02-23

Family

ID=23370005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003559435A Pending JP2005519891A (ja) 2002-01-15 2003-01-08 危篤状態の患者における罹病率および死亡率を低下させる方法

Country Status (6)

Country Link
US (1) US20050176631A1 (https=)
EP (1) EP1469880A4 (https=)
JP (1) JP2005519891A (https=)
AU (1) AU2003201810A1 (https=)
CA (1) CA2468610A1 (https=)
WO (1) WO2003059270A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
CN1890371A (zh) * 2003-12-10 2007-01-03 伊莱利利公司 成纤维细胞生长因子的21突变蛋白
WO2006028714A1 (en) * 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
EA011390B1 (ru) 2004-09-02 2009-02-27 Эли Лилли Энд Компани Мутантные белки (мутеины) фактора роста фибробластов 21
UA95903C2 (ru) 2005-02-24 2011-09-26 Дифьюжен Фармасьютикалз Ллк Транс-каротиноиды, их синтез, лекарственная форма и применение
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
EP2296690B1 (en) 2008-06-04 2016-11-30 Amgen, Inc Fgf21 mutants and uses thereof
JP5878757B2 (ja) 2008-10-10 2016-03-08 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
HRP20240135T1 (hr) * 2009-05-05 2024-04-12 Amgen Inc. Fgf21 mutanti i njihove upotrebe
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
US8324160B2 (en) * 2009-06-17 2012-12-04 Amgen Inc. Chimeric polypeptides and uses thereof
KR101875843B1 (ko) 2009-06-22 2018-07-06 디퓨젼 파마슈티컬즈 엘엘씨 확산 촉진 화합물 및 그 화합물 단독 또는 혈전 용해제와 합쳐진 화합물의 용도
EP2679234A3 (en) * 2009-12-02 2014-04-23 Amgen Inc. Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho
UA109888C2 (uk) * 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
KR101891357B1 (ko) 2010-06-02 2018-08-24 디퓨젼 파마슈티컬즈 엘엘씨 양극성 트랜스 카로티노이드의 경구용 제형
JP2014500248A (ja) 2010-11-05 2014-01-09 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗糖尿病化合物
JP6165168B2 (ja) 2011-12-22 2017-07-19 ファイザー・インク 抗糖尿病化合物
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
US11185523B2 (en) 2016-03-24 2021-11-30 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
MX2020002206A (es) 2017-09-08 2020-07-20 Bristol Myers Squibb Co Factor de crecimiento de fibroblastos 21 (fgf-21) modificado para usarse en metodos para tratar la esteatohepatitis no alcoholica (nash).
JP2018135329A (ja) * 2018-02-19 2018-08-30 ディフュージョン・ファーマシューティカルズ・エルエルシー 双極性トランスカロテノイド塩及びそれらの使用
CA3104686A1 (en) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Fgf-21 formulations
US20220017570A1 (en) 2018-11-05 2022-01-20 Bristol-Meyers Squibb Company Method for purifying pegylated protein
IL294534A (en) 2020-01-08 2022-09-01 Bristol Myers Squibb Co Fgf-21 conjugate formulations
JP2023538533A (ja) 2020-08-07 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716626B1 (en) * 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
WO2001036640A2 (en) * 1999-11-18 2001-05-25 Chiron Corporation Human fgf-21 gene and gene expression products
US20020081663A1 (en) * 2000-01-05 2002-06-27 Conklin Darrell C. Novel FGF homolog ZFGF11
US20030105302A1 (en) * 2000-03-08 2003-06-05 Nobuyuki Itoh Human FGF-23 gene and gene expression products
US20020151496A1 (en) * 2000-12-08 2002-10-17 Bringmann Peter W. Novel fibroblast growth factors
WO2003011213A2 (en) * 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity

Also Published As

Publication number Publication date
EP1469880A4 (en) 2006-04-26
US20050176631A1 (en) 2005-08-11
AU2003201810A1 (en) 2003-07-30
WO2003059270A2 (en) 2003-07-24
CA2468610A1 (en) 2003-07-24
EP1469880A2 (en) 2004-10-27
AU2003201810A8 (en) 2003-07-30
WO2003059270A3 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
JP2005519891A (ja) 危篤状態の患者における罹病率および死亡率を低下させる方法
EP0639079B1 (en) Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
US20040259780A1 (en) Method for treating diabetes and obesity
JP2005523877A (ja) 重病に関連する死亡率および罹患率の低減化方法
JPWO2018186480A1 (ja) 線維性疾患の治療薬
US20050250684A1 (en) Method for reducing morbidity and mortality in critically ill patients
CN112279920B (zh) FGF21 Fc融合蛋白、GLP-1 Fc融合蛋白及它们的组合治疗剂和用途
JPWO2006115274A1 (ja) 骨髄赤血球前駆細胞分化促進剤
CN113248628A (zh) 一种乳源多肽衍生物及其在制备肥胖症防治药物、保健品和食品添加物中的应用
JP2000511190A (ja) 外傷に起因する出血に見舞われたヒトにおけるｂｐｉタンパク質産物の治療用途
Hatton et al. Systemic metabolic effects of combined insulin-like growth factor–I and growth hormone therapy in patients who have sustained acute traumatic brain injury
KR20070008519A (ko) 패혈증 및 유착 형성의 치료 및 예방용 조직 보호성사이토카인
US11844771B2 (en) Methods of treating acute respiratory distress syndrome using colchicine
JPH06510292A (ja) 慢性肝疾患治療剤
JP4463885B2 (ja) 劇症肝炎疾患治療剤
US6303127B1 (en) Treatment of disease states
Pawlik et al. Central role of interleukin-6 in burn induced stimulation of hepatic amino acid transport
KR20000065178A (ko) 허혈-재관류손상을치료또는예방하는방법
JP7016125B2 (ja) 脳梗塞の治療薬
US20070141053A1 (en) Treatment of inflammatory respiratory diseases
Manjunathan et al. Biodiversity of the Adipocyte-Derived Hormone, Leptin
EP1608396B1 (en) Use of soluble cd14 for treatment of diseases
JPH083065A (ja) 肝臓障害に対する治療剤
CN116999538A (zh) 一种治疗细胞因子风暴的药物及其应用
JP2008094746A (ja) 炎症性疾患の治療又は予防剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051222

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090623